Where is BridgeBio headquartered?

BridgeBio is located in Palo Alto, CA.

Who invested in BridgeBio?

BridgeBio has 13 investors including Geekdom Fund And Geekdom Fund.

When was the last funding round for BridgeBio?

BridgeBio closed its lastf unding roundon Jul 19, 2017 from a Convertible Note round.

Company Information
Company Timeline (Coming Soon)

bridgebio.com

BridgeBio

BridgeBio is a California-based biotechnology company that develops and commercializes novel therapeutics for the treatment of genetic diseases.

Business Model:

Revenue: $88.7M

Employees: 501-1,000

Geographic Data

Address: 421 Kipling Street

City: Palo Alto

State: CA

Zip: 94301

Country: US

Financial Info

Stage:

post ipo debt

Raised Last:

$750M

Raised Total:

$2B

Social

Twitter

Crunchbase

Metrics

1,284,052Website Global Rank

22,629Website Monthly Traffic

Twitter Followers

Description

BridgeBio is a California-based biotechnology company that develops and commercializes novel therapeutics for the treatment of genetic diseases.

Contact Phone:
+16503919740

Contact Email:

IPO Details

BridgeBio went public on 6/26/2019 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
6/26/2019

IPO Valuation:
$2B

Ticker Symbol:
BBIO

IPO Price:
$17/share

Amount Raised:
$368M

Live

Opened: -/share

EBITDA	-
Total Cash	-
Total Debt	-
Total Revenue	-
Total Profit (Gross)	-
PE Ratio	-

Investments

Announced Date	Company	Transaction
4/2015	MyoKardia	Series B
8/2014	MyoKardia	Venture Round
1/2018	QED Therapeutics	Venture Round
8/2017	PellePharm	Series B
4/2018	Eidos Therapeutics	Series B
4/2018	Eidos Therapeutics	Series B
1/2018	QED Therapeutics	Venture Round
8/2017	PellePharm	Series B
4/2015	MyoKardia	Series B
8/2014	MyoKardia	Venture Round

Startup Demographics

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Funding Rounds

Announced Date	Transaction	Number of Investors	Money Raised	Lead Investors
1/2019	Equity	8	$299.2M	Perceptive Advisors Sequoia Capital AIG Investments Cormorant Capital Aisling Capital Viking Global Investors Hercules Capital Kohlberg Kravis Roberts Kohlberg Kravis Roberts Viking Global Investors Perceptive Advisors Sequoia Capital AIG Investments Cormorant Capital Aisling Capital Viking Global Investors Hercules Capital Kohlberg Kravis Roberts Kohlberg Kravis Roberts Viking Global Investors
11/2021	Post-IPO Debt		$750M
1/2021	Post-IPO Debt		$250M
2/2021	Post-IPO Secondary		-
3/2020	Post-IPO Debt		$475M
3/2016	Series B	1	$6.9M	Kohlberg Kravis Roberts Kohlberg Kravis Roberts
5/2017	Series B	1	$33.1M	Kohlberg Kravis Roberts Kohlberg Kravis Roberts
6/2019	IPO		$348.5M
9/2017	Series C	7	$135M	Janus Fund Perceptive Advisors Kohlberg Kravis Roberts Viking Global Investors AIG Investments Aisling Capital Cormorant Capital Janus Fund Perceptive Advisors Kohlberg Kravis Roberts Viking Global Investors
1/2021	Post-IPO Debt		$650M
2/2021	Post-IPO Secondary		-

Acquisitions

Announced Date	Name	Price
10/2020	Eidos Therapeutics

Employee Demographics

Employee Departments

Employee States

Similar Companies

Uniview Singapore VEID	Revenue: 0 - 100000 Employees: Industry: Software	Details
Konkuk University Medical Center	Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education	Details
Daemon Technologies	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain	Details
Ace International Trade	Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial	Details
An Hòa Communications	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising	Details